Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 250 of 994 entries
View as:

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

Phase: N/A Priority: Normal
NCT ID: NCT02833857 Org: User:
Start: 03/14/17 End: 10/31/18 Due: 10/31/19

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02303821 Org: User:
Start: 02/16/15 End: 06/28/24 Due: 06/28/25

Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00503490 Org: User:
Start: 06/30/07 End: 12/31/07 Due: 12/31/08

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02561962 Org: User:
Start: 11/20/15 End: 04/21/22 Due: 04/21/23

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis

Phase: N/A Priority: Normal
NCT ID: NCT02429882 Org: User:
Start: 05/31/15 End: 05/31/15 Due: 05/31/16

A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02291614 Org: User:
Start: 11/27/14 End: 01/09/18 Due: 01/09/19

PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01212770 Org: User:
Start: 09/30/10 End: 02/09/17 Due: 02/09/18

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients

Phase: N/A Priority: Normal
NCT ID: NCT01270347 Org: User:
Start: 01/31/11 End: 06/30/13 Due: 06/30/14

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Phase: N/A Priority: Normal
NCT ID: NCT03792841 Org: User:
Start: 02/05/19 End: 06/29/23 Due: 06/29/24

Treatment for Patients With Osteoarthritis (OA)

Phase: N/A Priority: Normal
NCT ID: NCT00110942 Org: User:
Start: 02/28/05 End: 11/30/05 Due: 11/30/06

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06311721 Org: User:
Start: 09/09/24 End: 05/29/28 Due: 05/29/29

A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

Phase: N/A Priority: Normal
NCT ID: NCT00321464 Org: User:
Start: 04/01/06 End: 04/04/12 Due: 04/04/13

Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients

Phase: N/A Priority: Normal
NCT ID: NCT03927144 Org: User:
Start: 05/15/19 End: 09/30/22 Due: 09/30/23

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT02291588 Org: User:
Start: 12/31/07 End: 06/30/10 Due: 06/30/11

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

Phase: N/A Priority: Normal
NCT ID: NCT01788046 Org: User:
Start: 03/12/13 End: 05/09/14 Due: 05/09/15

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Phase: N/A Priority: Normal
NCT ID: NCT05361395 Org: User:
Start: 08/24/22 End: 08/28/28 Due: 08/28/29

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Phase: N/A Priority: Normal
NCT ID: NCT05704738 Org: User:
Start: 04/20/23 End: 11/27/25 Due: 11/27/26

A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01677858 Org: User:
Start: 07/04/12 End: 10/31/18 Due: 10/31/19

Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

Phase: N/A Priority: Normal
NCT ID: NCT01543204 Org: User:
Start: 02/01/12 End: 05/29/15 Due: 05/29/16

START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism

Phase: N/A Priority: Normal
NCT ID: NCT00132431 Org: User:
Start: 07/31/04 End: 07/31/05 Due: 07/31/06

Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab

Phase: N/A Priority: Normal
NCT ID: NCT00259740 Org: User:
Start: 11/30/05 End: 12/31/11 Due: 12/31/12

AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib

Phase: N/A Priority: Normal
NCT ID: NCT00467025 Org: User:
Start: 05/31/07 End: 06/30/14 Due: 06/30/15

Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective

Phase: N/A Priority: Normal
NCT ID: NCT02504476 Org: User:
Start: 08/31/15 End: 02/29/16 Due: 02/28/17

A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.

Phase: N/A Priority: Normal
NCT ID: NCT02174861 Org: User:
Start: 06/30/14 End: 05/26/17 Due: 05/26/18

Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00352950 Org: User:
Start: 03/31/06 End: 02/29/08 Due: 02/28/09